[go: up one dir, main page]

AR058319A1 - N-(fluoropirazinil)fenilsulfonamidas como moduladores del receptor ccr4 de quimioquinas - Google Patents

N-(fluoropirazinil)fenilsulfonamidas como moduladores del receptor ccr4 de quimioquinas

Info

Publication number
AR058319A1
AR058319A1 ARP060105466A ARP060105466A AR058319A1 AR 058319 A1 AR058319 A1 AR 058319A1 AR P060105466 A ARP060105466 A AR P060105466A AR P060105466 A ARP060105466 A AR P060105466A AR 058319 A1 AR058319 A1 AR 058319A1
Authority
AR
Argentina
Prior art keywords
phenylsulphonamids
fluoropirazinil
chriochines
ccr4
modulators
Prior art date
Application number
ARP060105466A
Other languages
English (en)
Inventor
David Cheshire
Nicholas Kindon
Bryan Roberts
Antonio Mete
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR058319A1 publication Critical patent/AR058319A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Procesos e intermediarios que se utilizan en su preparacion, composiciones farmacéuticas que los contiene y su uso en terapia. Reivindicacion 1:Un compuesto caracterizado porque responde a la formula (1) o una sal del mismo aceptable para uso farmacéutico: donde R1 se selecciona entre metilo, Cl y F; R2 se selecciona entre metilo, Cl y F; R3 es metoxi; uno de R4 y R5 es F y el otro de R4 y R5 se selecciona entre H e hidroximetilo.
ARP060105466A 2005-12-12 2006-12-12 N-(fluoropirazinil)fenilsulfonamidas como moduladores del receptor ccr4 de quimioquinas AR058319A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0502733 2005-12-12

Publications (1)

Publication Number Publication Date
AR058319A1 true AR058319A1 (es) 2008-01-30

Family

ID=38163190

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105466A AR058319A1 (es) 2005-12-12 2006-12-12 N-(fluoropirazinil)fenilsulfonamidas como moduladores del receptor ccr4 de quimioquinas

Country Status (20)

Country Link
US (2) US20080293742A1 (es)
EP (1) EP1968951B1 (es)
JP (1) JP2009519332A (es)
KR (1) KR20080091139A (es)
CN (1) CN101370793B (es)
AR (1) AR058319A1 (es)
AT (1) ATE513819T1 (es)
AU (1) AU2006325573A1 (es)
BR (1) BRPI0619602A2 (es)
CA (1) CA2631342A1 (es)
CL (1) CL2006003449A1 (es)
EC (1) ECSP088603A (es)
ES (1) ES2366807T3 (es)
IL (1) IL191761A0 (es)
NO (1) NO20083070L (es)
RU (1) RU2008122401A (es)
TW (1) TW200730512A (es)
UY (1) UY29999A1 (es)
WO (1) WO2007069978A1 (es)
ZA (1) ZA200804921B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328007B (en) 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
EP2749554B1 (en) * 2009-04-22 2017-12-20 SMA Therapeutics, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
WO2015027296A1 (en) * 2013-09-02 2015-03-05 The University Of Melbourne A method of treatment
CN104447756A (zh) * 2014-11-10 2015-03-25 常州大学 一种五氟磺草胺中间体的制备方法
CN104402890A (zh) * 2014-11-10 2015-03-11 常州大学 一种制备五氟磺草胺的方法
AU2018360766B2 (en) 2017-11-06 2024-09-19 Rapt Therapeutics, Inc. Anticancer agents
CN110028501B (zh) 2018-01-12 2022-02-22 迈德欣国际有限公司 化合物及其制备方法和用途
CN108929279A (zh) * 2018-07-27 2018-12-04 同济大学 一种含氟氨基吡嗪类化合物及其制备方法与应用
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB928151A (en) * 1959-07-14 1963-06-06 Farmaceutici Italia Pyrazine derivatives
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
ATE312096T1 (de) 2001-12-18 2005-12-15 Neue verbindungen
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0302304D0 (sv) * 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20080293742A1 (en) 2008-11-27
ATE513819T1 (de) 2011-07-15
CN101370793B (zh) 2012-01-04
BRPI0619602A2 (pt) 2011-10-11
UY29999A1 (es) 2007-07-31
KR20080091139A (ko) 2008-10-09
CA2631342A1 (en) 2007-06-21
ECSP088603A (es) 2008-08-29
WO2007069978A1 (en) 2007-06-21
HK1121760A1 (en) 2009-04-30
AU2006325573A1 (en) 2007-06-21
IL191761A0 (en) 2008-12-29
NO20083070L (no) 2008-08-28
EP1968951B1 (en) 2011-06-22
JP2009519332A (ja) 2009-05-14
EP1968951A1 (en) 2008-09-17
ZA200804921B (en) 2009-09-30
CN101370793A (zh) 2009-02-18
TW200730512A (en) 2007-08-16
US20100144759A1 (en) 2010-06-10
RU2008122401A (ru) 2010-01-20
CL2006003449A1 (es) 2008-02-08
ES2366807T3 (es) 2011-10-25

Similar Documents

Publication Publication Date Title
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY28756A1 (es) Compuestos
UY30610A1 (es) Moduladores de mglur5
UY28764A1 (es) Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
UY29875A1 (es) Compuestos quimicos
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
SE0403171D0 (sv) New compounds
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure